BH3:FRA
PTC Therapeutics, Inc.
56,26 €
arrow_downward
−0,92%(−0,52) 1 D
30. sep., 22:00:00 GMT+2 · EUR
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for BH3 …
Ã…pne
56,26 €
Høy
56,26 €
Lav
56,26 €
Markedsverdi
5,41Â mrd.
Snittvolum
0,00
Volum
0,00
52 u høy
77,02 €
52Â u lav
50,00 €
Antall ansatte
991
Ã…pne
56,26 €
Høy
56,26 €
Lav
56,26 €
Markedsverdi
5,41Â mrd.
Snittvolum
0,00
Volum
0,00
52 u høy
77,02 €
52Â u lav
50,00 €
Antall ansatte
991
Nyhetssaker
Fra nettkilder og nyhetspartnere
Stock Titan
·
for 3 timer siden
A director proposes selling $782K in option-exercised PTC Therapeutics (PTCT) shares.
Profil
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
Om PTC Therapeutics, Inc.
Administrerende direktørMatthew B. Klein
Ansatte991
Grunnlagt1. jan. 1998
HovedkontorWarren, New Jersey, USA
Sektor-
Nettstedptcbio.com